Our collaborators at University College London (UCL) Biochemical Engineering Department have presented a poster on the use of M-SAN HQ for purification of lentivirus vectors for cell therapy applications. The poster entitled: “Removal of contaminating DNA in downstream processing of lentiviral vectors” was presented at the 29th Annual European Society for Cell and Gene Therapy at the EICC in Edinburgh, …
ArcticZymes Technologies will be presenting during Pareto Securities’ 13th Annual Healthcare Conference in Stockholm, Sweden
CEO, Dr. Jethro Holter will offer a presentation on Thursday, 8 September 2022 at 15:15. Join us for an update on the latest development at ArcticZymes!
Q2 2022 report and presentation
Tromsø, Norway, 18th August 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 30.4 million (21.3) and an EBITDA of NOK 9.5 million (6.0) for the second quarter of 2022. Highlights from Q2 and first 6 months 2022 ArcticZymes Technologies (AZT) had Q2 sales of NOK 30.4 million growing by 43% (Q2 2021: NOK 21.3 million) and sales for …
Welcome to the team!
We welcome Dirk Hahneiser to ArcticZymes Technologies who joins us as Vice President of Business Development and Marketing. Dirk will lead ArcticZymes Technologies´ global business development team and further develop the company´s commercial and marketing strategy. We are excited to have Dirk aboard and look forward to working with him.